Navigation Links
Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Date:4/28/2011

NEW YORK, April 28, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals (Nasdaq: KERX) today announced the final dataset from the Phase 3 short-term clinical trial of Zerenex (ferric citrate) for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis.  The Zerenex data was presented earlier today at the National Kidney Foundation Spring Clinical Meetings being held in Las Vegas, Nevada, in an oral presentation by David S. Goldfarb, M.D., Clinical Chief of Nephrology, NYU Langone Medical Center, Professor of Medicine & Physiology, NYU School of Medicine.  On November 30, 2010, the Company issued a press release announcing positive top-line results from this Phase 3 short-term study.

Phase 3 short-term study designThis Phase 3 study was a multicenter, randomized, open-label trial with a two-week washout period, following which patients were randomized 1:1:1 to receive a fixed dose of Zerenex of either 1 gram, 6 grams or 8 grams per day for a treatment period of 28 days. Zerenex was administered using a 1 gram oral caplet formulation, hence, the fixed-dose arms of 1 gram, 6 grams and 8 grams per day represent 1, 6 and 8 pills per day, respectively.

One hundred fifty-one dialysis patients were enrolled into the study. The Intent-to-Treat (ITT) group included 146 patients, representing all patients who took at least one dose of Zerenex and provided a Baseline (at the end of washout) and at least one post-Baseline efficacy assessment. Efficacy assessments were taken weekly starting at Baseline and subsequently at days 7, 14, 21 and 28.

EFFICACY DATA ANALYSESThe primary endpoint of the study was to determine whether there was a dose response in the change in serum phosphorus from Baseline to Day 28 in the ITT group, using a regression analysis to evaluate this objective.

The study met the primary endp
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
2. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
3. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
4. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
5. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
6. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
7. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... DES MOINES, Iowa (PRWEB) July 23, 2014 ... will join the business as vice president of Agricultural ... from Mendel Biotechnology where he served most recently as ... brings extensive biotechnology and business leadership in the seed ... DuPont Pioneer,” said Paul E. Schickler , president ...
(Date:7/23/2014)... Sciences, Inc. (OTCQB: GBLX), a medical cannabis research and development ... marijuana dispensary locations in Las Vegas, Nevada ... Clark County, Nevada dispensary for which the company ... GrowBLOX Sciences, CEO Craig Ellins stated, "We ... in the City of Las Vegas . ...
(Date:7/23/2014)... 2014 OncLive® is pleased to ... joined its Strategic Alliance Partnership program. , ... UNC Lineberger will have the opportunity to work ... its cutting-edge research initiatives, community-directed cancer prevention programs, ... work with OncLive to educate their peers by ...
(Date:7/22/2014)... Web) July 21, 2014 (PRWEB) July 23, 2014 ... Biomaterials, at Rutgers University. , The goal ... ideas across the full spectrum of scientists working ... research and development topics that represent the most ... been programmed to:,     Provide faculty ...
Breaking Biology Technology:DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2
... 2011 Celtaxsys, Inc., a private biopharmaceutical company defining new ... veteran, H. Daniel Perez, M.D., to its Board of Directors ... has joined the Celtaxsys team," says Dr. Michael R. Hanley, ... more than 25 years of high level pharmaceutical executive experience ...
... 5, 2011 Northwest Biotherapeutics (OTC.BB: NWBO) today announced ... financing arrangements, including a $3 million investment already received, ... funding on fixed, specified and favorable terms, at such ...  This series of financing arrangements will provide a strong ...
... 2011 Recent biopharmaceutical product launches have produced both ... area. Faced with a continually evolving launch landscape, organizations ... in the current launch environment. In ... success factors and failure points facing new product launches, ...
Cached Biology Technology:Dr. H. Daniel Perez Joins Celtaxsys Board of Directors 2Northwest Biotherapeutics Announces Series of Financing Arrangements 2Northwest Biotherapeutics Announces Series of Financing Arrangements 3Northwest Biotherapeutics Announces Series of Financing Arrangements 4Creating a Road Map for Successful Cardiovascular New Product Launch 2
(Date:7/23/2014)... Cell Foundation (NYSCF) and Beyond Batten Disease Foundation (BBDF) ... and explore new treatments and ultimately find a cure ... , NYSCF scientists will create induced pluripotent stem (iPS) ... by juvenile Batten disease as well as unaffected family ... back the clock" on skin cells to a time ...
(Date:7/23/2014)... by ischemic preconditioning has been confirmed by many ... a study released in the Neural Regeneration ... Yong Liu and co-workers from Tongji Hospital Affiliated ... and Technology, China performed cerebral ischemic preconditioning in ... explored the mechanism underlying the neuroprotective effect of ...
(Date:7/23/2014)... are working to restore New Hampshire and Maine,s only ... has found that in the last decade, cottontail populations ... seen a 50 percent contraction of their range. ... at risk of becoming extinct in the region, according ... of New Hampshire College of Life Sciences and Agriculture ...
Breaking Biology News(10 mins):NYSCF partners with Beyond Batten Disease Foundation to fight juvenile Batten disease 2NYSCF partners with Beyond Batten Disease Foundation to fight juvenile Batten disease 3UNH NHAES researchers work to save endangered New England cottontail 2UNH NHAES researchers work to save endangered New England cottontail 3
... Tests on the influence that a stress-related hormone has ... on understanding how it influences human learning, according to ... Professor in Comparative Human Development, has found that when ... quickly if they have a modest amount of cortisol, ...
... been lifted at the request of the PIO. , Without ... sideways, even though they lack flippers or fins. University of ... pelvic, abdominal and rib muscles to shift their lungs like ... the head when they surface and sideways when they roll. ...
... the Genome Sequencing Center (GSC) at Washington University in St. ... of the corn genome. In the fall of ... Agriculture (USDA) and the Department of Energy (DOE), awarded $32 ... goal of the project led by the Washington University GSC ...
Cached Biology News:Research with squirrels provides clues on hormone's role in human learning 2How alligators rock and roll 2How alligators rock and roll 3How alligators rock and roll 4How alligators rock and roll 5All eyes and ears on the corn genome 2All eyes and ears on the corn genome 3
... sufficient materials for 1,464 array sample elements. , , ... , Blocker BSA in PBS (10X): 50 ml , ... Saline: 8 packs , 10% Tween-20: 2 x 10 ... x 25 ml , SuperSignal West Pico Stable Peroxide: ...
... Mouse polyclonal antibody raised against ... Immunogen: XAGE2 ... a.a) partial recombinant protein with ... Accession Number: NM_130777 ...
... proteins are used to immunize rabbits. , Agro-Bio ... quantity of antigen and quality of the antibodies ... per protocol in order to avoid animal variability. ... is approximately 75 mL per rabbit.,150 to 250 ...
...
Biology Products: